ERBB2 and adenocarcinoma: For example, in the case of a patient with adenocarcinoma of the esophagogastric junction and the ERBB2 amplification, clinician feedback noted that the MTB recommendation (Trastuzumab-Deruxtecan) was based on the pathology HER2 DAKO 3+ Score, which was due to the ERBB2 Amplification.